Background
Lung emphysema and fibrosis are generally considered to be two diseases that totally differ in their morphological aspects and pathogenic mechanisms.
However, both these pathologies may be present at the same time in lungs of mice after cigarette-smoke exposure [
1], in animals instilled intratracheally with BLM or other substances [
2‐
5], as well as in human lungs [
6]. In particular, in smokers and ex-smokers, centrilobular emphysema may be associated with some subsets of idiopathic interstitial pneumonias (IIP), namely "desquamative interstitial pneumonia" (DIP), "respiratory bronchiolitis-associated lung disease" (RB-ILD), and finally "idiopathic pulmonary fibrosis" (IPF) also characterized by the histological pattern of "usual interstitial pneumonia" (UIP). This has been clearly outlined in a recent document of the ATS/ERS defining the clinical manifestations, pathology and radiologic features of patients with IIP [
7]. These data all together suggest a common pathway in the development of these two pathologies.
According to a current view, pulmonary emphysema originates from an imbalance between elastinolytic proteases and their naturally occurring inhibitors. In particular, neutrophil elastase (NE), and other elastolytic proteases, such as cathepsin G, and macrophage elastase are thought to be the main causative factors of tissue damage in this condition. This hypothesis is based on a mixture of evidence from animal models, broncho-alveolar lavage fluid (BALF) data,
in vitro experiments, and from the high incidence of emphysema in homozygous subjects with a deficiency of α
l-proteinase inhibitor (α
1-PI) [
8,
9].
Recently, it has been reported that α
1-PI, the secretory leukocyte protease inhibitor (SLPI), as well as the synthetic inhibitor of leukocyte elastase ONO-5046, significantly attenuate the fibrotic response to BLM in rodents [
10‐
12]. In man, the inactivation of proteolytic enzymes may also be a critical event in normal repair, and as demonstrated in infants with respiratory distress syndrome, lack of antiprotease activity is associated with chronicity and development of fibrosis [
13].
Thus, these studies suggest a significant role for the antiprotease screen not only in the development of pulmonary emphysema but also in the modulation of fibrotic lesions. This is further supported by studies carried out in BLM-challenged mice either with a genetic deficiency in α
1-PI [
4], or with a targeted deletion of the NE gene [
14].
As previously reported by us, BLM administration induces alveolitis and fibrosis in α
1-PI deficient mice. It also results in enlargement of air spaces that may be due either to loss of alveolar septa and/or retraction forces caused by the fibrotic process [
4].
In this study we investigate whether NE may constitute a pathogenic link between emphysema and fibrosis. This was done in two animal models in which these two pathologies were induced either by BML or chronic exposure to cigarette smoke. In order to assess the protease-dependence of the BLM-induced lung lesion under our experimental conditions, a group mice was treated with 4-(2-aminoethyl)-benzenesulfonyl fluoride hydrochloride, a serine proteinase inhibitor fully active against NE [
15].
Discussion
Although lung emphysema and fibrosis may result from two distinct and apparent opposite processes, they may coexist either in different areas, or in a same area of the lung of humans and animals. The development and the degree of these morphological responses that generally follow, or exacerbate, an acute or chronic inflammation can be influenced by many individual factors, such as cytokine production, variation in collagen synthesis and deposition, antiprotease screen and antioxidant status [
23‐
30].
The findings reported in this paper strongly suggest that NE may represent a common factor affecting the development of both emphysema and fibrosis.
In particular, we demonstrate that in mice BLM-treated which are genetically deficient in αl-PI (
i) emphysema and fibrosis may coexist either in different areas, or in a same lung area; (
ii) the development of emphysema precedes that of fibrosis; (
iii) the development of emphysematous lesions, shortly after BLM administration, is preceded by an alveolar elastolytic burden and is matched by a marked decrease in lung desmosine content; and finally, (
iiii) an evident staining for TGF-β and TGF-α is observed when an increased neutrophil elastase burden can also be demonstrated. Similarly, we found in lungs of mice after cigarette-smoke exposure that (
i) emphysema and fibrosis may be present in the same lung; (
ii) the development of the emphysematous lesions occur at earlier time points than that of the fibrotic foci, and
(iii) a positive immunohistochemical reaction for neutrophil elastase is associated with a positive reaction for TGF-β and TGF-α two major fibrogenic cytokines (i.e. [
31,
32] in foci of cellular proliferation, and in areas of fibrosis.
Taken all together these results indicate that the air-space enlargements observed in mice with a genetic deficiency of serum αl-PI, early after BLM, represent areas of "true" emphysema caused by a proteolytic attack and characterised by lung desmosine loss. The strong immunoelectron microscopical reaction for NE found on alveolar septa of αl-PI deficient mice early after BLM and in DBA/2 mice after cigarette smoke suggests that NE may represent a common factor affecting the development of both emphysema and fibrosis.
This hypothesis is further supported by the data obtained in BLM-treated C57 B1/6J mice in which both emphysema and fibrosis were significantly attenuated by the use of a serine proteinase inhibitor active against NE. Of interest, in these animals no immunological reaction for TGF-α and only a faint positive staining for TGF-β could be demonstrated. Although there is no ideal animal model, including the BLM one, that mimics human idiopathic pulmonary fibrosis, the data reported here support a role for proteases, and in particular for NE, in both these two pathologies.
It is well know that proteases released by inflammatory cells recruited at the site of inflammation may be involved in the intracellular as well as extracellular route of catabolism of interstitial proteins. These proteases may play an important role in tissue injury and repair by degrading the components of the extracellular matrix [
33]. During the reparative responses they can remove scar tissue influencing in this way the morphological end-point.
It is generally accepted that NE plays a role in the development of emphysematous lesions. It acts on a large variety of substrates, in particular elastin, collagens, fibronectin, laminin and proteoglycans [
23]. Recent studies suggest that this enzyme may modulate the fibrotic response also by interacting with the cytokine network. NE can activate or inactivate by proteolytic cleavage several cytokines, receptors and polypeptide growth factors implicated in inflammation and reparative phases of the fibrotic response [
34‐
37].
In this regard, NE constitutes an important factor for the generation of soluble TGFα [
32], a potent mitogenic cytokine for mesenchymal cells. In fact, TGFα is activated by the cleavage of the membrane precursor pro-TGFα by elastase [
38,
39].
Additionally, NE modulates TGF-β bioactivity [
35] either directly by releasing TGF-β1 from the extracellular matrix [
40] or indirectly
via MMP-12 [
41].
Of interest, we found that TGFα and TGFβ immunoreactivity was significantly high in mice that develop foci of subpleural fibrosis after cigarette-smoke or BLM treatment when a positive reaction for mouse NE on the alveolar septa was found. Although the association between the development of foci of subpleural fibrosis and a positive reaction for mouse NE on the alveolar septa does not prove a causal relationship, the data presented here strongly support the hypothesis that NE may represent a common pathogenic link between emphysema and fibrosis.
Competing interests
The author(s) declare that they have no competing interests.
Authors' contributions
ML played a major role in the design of the study, acquisition, analysis and interpretation of data and drafting the manuscript. BB and BL performed the histological and morphometrical analyses, and contributed to the interpretation of the results. EC and SF performed histochemical and biochemical analyses, carried out animal studies and participated in the interpretation of data. PAM performed some of the morphometrical analysis and contributed to the interpretation of data. GL conceived and coordinated the study, participated in the design of the study, analysis and interpretation of data and drafting the manuscript. All authors read and approved the final manuscript.